Anti-Thrombomodulin antibody [B-A35] (ab27393)

Overview

  • Product name
    Anti-Thrombomodulin antibody [B-A35]
    See all Thrombomodulin primary antibodies
  • Description
    Mouse monoclonal [B-A35] to Thrombomodulin
  • Specificity
    Recognises the soluble thrombomodulin antigen
  • Tested applications
    Suitable for: Flow Cytmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    TF1 cell line

  • Positive control
    • Monocytes

Properties

Applications

Our Abpromise guarantee covers the use of ab27393 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt Use at an assay dependent concentration. ab170190-Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.

Target

  • Function
    Thrombomodulin is a specific endothelial cell receptor that forms a 1:1 stoichiometric complex with thrombin. This complex is responsible for the conversion of protein C to the activated protein C (protein Ca). Once evolved, protein Ca scissions the activated cofactors of the coagulation mechanism, factor Va and factor VIIIa, and thereby reduces the amount of thrombin generated.
  • Tissue specificity
    Endothelial cells are unique in synthesizing thrombomodulin.
  • Involvement in disease
    Defects in THBD are the cause of thrombophilia due to thrombomodulin defect (THR-THBD) [MIM:188040]. A hemostatic disorder characterized by a tendency to thrombosis.
    Defects in THBD are a cause of susceptibility to hemolytic uremic syndrome atypical type 6 (AHUS6) [MIM:612926]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.
  • Sequence similarities
    Contains 1 C-type lectin domain.
    Contains 6 EGF-like domains.
  • Post-translational
    modifications
    N-glycosylated.
    The iron and 2-oxoglutarate dependent 3-hydroxylation of aspartate and asparagine is (R) stereospecific within EGF domains.
  • Cellular localization
    Membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • AHUS 6 antibody
    • AHUS6 antibody
    • BDCA 3 antibody
    • BDCA3 antibody
    • CD 141 antibody
    • CD141 antibody
    • CD141 antigen antibody
    • Fetomodulin antibody
    • Thbd antibody
    • THPH12 antibody
    • THRM antibody
    • Thrombomodulin antibody
    • TM antibody
    • TRBM_HUMAN antibody
    see all

Images

  • A typical staining pattern with the ab27393 of monocytes

References

ab27393 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab27393.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up